PurIST Classifier Validated for Pancreatic Cancer Therapy
Real-World Validation of the Purity Independent Subtyping of Tumors Classifier for Informing Therapy Selection [PurIST @TempusAI] in Pancreatic Ductal Adenocarcinoma [Sep 4, 2025] @stephwen et al. @JCOPO_ASCO https://t.co/R24DErvaB4 #pancsm #PrecisionMedicine https://t.co/40LqNDQJHo
RUNX1 Identified as Key to Rejuvenate Aging T Cells
Discovery of a factor (RUNX1) that pinpoints T cell senescence and restoring its functionality achieves T cell rejuvenation. Significant implications in older adults with loss of immune system protection. https://t.co/X58DvzIUXY @ImmunityCP https://t.co/hzL3zFiPMm
Continuous Fermentation Cuts Costs, Beats Traditional Bioreactors
The biomanufacturing bottleneck isn't biology. It's economics. Building bigger bioreactors doesn't fix unit costs. https://t.co/2RAcw704uk's bet: continuous fermentation decouples growth from production, keeps cells in an ultra-productive state for weeks, and runs like a conveyor belt instead of a batch process. ...
GLP‑1 Receptors Protect Liver in Mouse MASH Model
Adding to the GLP-1 drug weight-loss independent effect benefit : impact on liver sinusoidal endothelial cell GLP-1 receptors for liver protection in mouse MASH model @Cell_Metabolism @DanielJDrucker @ChusaGzlzRellan https://t.co/0A13QYgm05
Low P‑tau217 Indicates Minimal Alzheimer’s Risk in Seniors
Another study indicative of predictive power of p-tau217 for Alzheimer's disease in cognitively unimpaired older adults (mean age 71 at baseline) A very low p-tau217 denoted minimal risk https://t.co/6RPJcCloWI https://t.co/XikzsvJjhM
In‑vivo Base Editing Rescues Zellweger Disorder in Mice
Today in @natBME we report an in vivo base editing strategy that corrects a common disease-causing mutation and rescues pathology in a mouse model of Zellweger spectrum disorder (ZSD) and restore peroxisomal function in patient derived cells. This work highlights...
Lilly to Acquire CrossBridge Bio in $300 M Deal
NEW: Eli Lilly has agreed to acquire CrossBridge Bio, the Houston-based ADC specialist led by @Mykalt45 I talked with Michael Torres on his run as a first-time CEO ending with a potential $300M deal: https://t.co/PPk3ZWL5SR
Anavex Shows Promise, but EMA Hurdles Loom
Macro: autophagy links autism & Alzheimer’s. Key: Anavex blarcamesine restores autophagy; positive Phase IIb/III data. Risk: EMA pushback. Insight: speculative long, tight stop. 🔬 — Viktor Kopylov, PhD, CFA More insights: t.me/si14Kopylov
TVTX Surges 45% After FDA Approval, Long Calls Lead
$TVTX jumps 45% on FDA approval, always liked this one, continues to work 5K Apr. 32.5 long calls leads the way https://t.co/g7Ga8FIJve
SGLT2 Inhibitors Protect Kidneys, Yet Raise Non‑Renal Risks
Sodium-Glucose Cotransporter-2 Inhibitors and Acute Kidney Injury Risk: A Systematic Review and Meta-Analysis of Randomized Trials "SGLT2is conferred substantial renoprotective benefits but increases the risk of certain nonrenal AEs." https://t.co/n0yhZgcShy
Crossing the SynBio Valley of Death with Proven Solutions
Most synbio companies die between "works in the lab" and "works at scale." Freedom-to-operate issues, process robustness, CMC readiness. The valley of death is real and it swallows good science. @IngenzaLtd has been helping teams cross it for 20 years. Leonardo Magneschi...
Proline‑mediated Dichloromethyl Tagging Enables Ultra‑pure Drug Synthesis
A new method uses the amino acid proline to precisely attach dichloromethyl groups to complex molecules, enabling ultra-pure drug synthesis with built-in quality control and expanding possibilities for advanced medicine design. drugdiscovery
Personal Loss Exposes Danger of Dismissing Cancer Breakthroughs
Hype is bad. That includes calling an unprecedented advance in cancer treatment hype when it is not. Don’t think about the knee jerk comment this tweet is replying to. Think about this man’s wife getting three vacations.
Why Anthropic Chose Coefficient Bio Over Bigger Rivals?
Reading up on the Coefficient Bio deal. I totally get the industrial logic around why Anthropic should care about drug discovery. But why this particular company? There's lots of more scaled players doing this. Can anyone educate me? https://t.co/akFVmRUaYw
DeepSeqAI Trains on Function to Future‑proof Biologics
Most AI protein tools are trained on structure. DeepSeqAI trains on function. They're running billions of experimental protein-protein interactions through their platform to map biologics against viruses, immune receptors, and the entire human proteome. The goal: candidates that hold up against...
CRISPR Turns 25: Explore Its Past, Present, Future
Introducing the GEN Keynote Webinar: "CRISPR at 25: The Past, Present, and Future of Genome Editing" Guest speaker: Rodolphe Barrangou @CRISPRchef May 4, 2026: noon ET/9 am PT Sponsored by @elevatebio https://t.co/cYsSsaod4Y via @GENbio
Merck's $30B Offer Now Exceeds Revolution's Market Cap
Reminder that Merck tried to buy Revolution for $28-$32B (per Jan reporting from FT), vs current market cap after today's great data of $26.5B https://t.co/hoq2P0oiG9
Busy Biotech Day Highlights Promising Advances and Insightful Commentary
As usual, excellent summary by @ldtimmerman @timmermanreport of busy and promising biotech news day - as always delivered w insight and heart (especially thoughtful comments re: revmed drug in context of poignant recent @BenSasse interview)
FDA Zeroes in on Houman Hemmati for CBER Lead
FDA narrows in on search for new biologics and vaccines leader - and we’re hearing @houmanhemmati is a top contender for CBER - https://t.co/qMx8wv32fG
Delaying Generics Boosts Profits Far More than Small Gaps
That gap doesn't look like it could be the largest price-fixing scam in history. it looks like 4% of a generic drug's price. Brand drugs sell for 10-20 times as much as generics, Delaying generic entry by even 6 months...
Off‑the‑Shelf CAR‑T Shows Promise Delaying Lymphoma Relapse
Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma https://t.co/UrSNYpQFqB by @gwendolynawu $ALLO + 25%
Pancreatic Cancer Drug Nearly Doubles Survival in Trial
Revolution pancreatic cancer drug nearly doubles survival in key trial https://t.co/SvJicU0LIz @ByJonGardner $RVMD + 38%
AI Company Becomes First Autonomous Drug Prescriber in Utah
An editorial @JAMA_current on @doctronic (the AI company now prescribing renewal medications without physician involvement in Utah) entitled "The First AI Drug Prescriber" https://t.co/Wo1rVhnr4s https://t.co/hAcYbYLmIv
Revolution Medicines' Pancreatic Cancer Drug Shows Late‑Stage Success
This is big. All cancers suck. Pancreatic somehow manages to suck even more. Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial https://t.co/rFVsvi0mQD
Multiplexed In‑Vivo Screening Drives Next‑Gen Drug Development
Multiplexed in vivo screening is the future of drug development. @ManifoldBio is multiplexing protein therapies in vivo. @GordianBio is multiplexing gene therapies in vivo. @waypointbio is multiplexing cell therapies in vivo. GT Bio is multiplexing LNPs in vivo. 50Y portcos all https://t.co/DT2AwXbKtB
ALLO May
Has $ALLO found a niche for allo Car-T at last? It's early days, so the answer is maybe. Via @APEXONCO -> https://t.co/bO3A1hpAY8
Rigorous Trials, Not Hype, Prove Cancer Drug Value
Today's $RVMD study outcome in pancreatic cancer is a good lesson for all the $IBRX @DrPatrick fans. Stop with all the hand-waving "cancer cure" podcasting social media nonsense. Shut up and run well-designed clinical trials with definitive endpoints. If you have...
Nanodiscs Reveal Antibody Interactions for HIV, Ebola Vaccines
Nanodisc technology enables viral surface proteins from HIV and Ebola to be studied within lifelike membrane environments, offering new insights into antibody interactions and accelerating the development of next-generation vaccines. vaccinedesign
Pancreatic Cancer Trials Yield Only 1‑2 Month Gains
I remember years ago in pancreatic cancer trials you were realistically looking for 1 to 2 months improvement in survival (at best) in pancreatic cancer trials. Bravo $RVMD.👏
Second‑line RVMD Improves Pancreatic Cancer Survival over First
As noted by others, the $RVMD dara mOS in 2nd line PDAC is better than mOS for current first-line regimens.
Low‑Cost Vaccine Creator Outshines Rogan’s Diet Critique
I make low cost vaccines for global health, including a Covid vaccine technology for $2-3 per dose reached 100 million people, bypassed big pharma, didn’t make money, and all these Rogan types can talk about is a joke I made...
One Gene Therapy Platform Could Cure Obesity and More
Eric Kelsic makes the compelling case on using gene therapy technology to eventually treat common diseases, like obesity: “Fundamentally, we all share the same genetics." Because our bodies run on the same genetic blueprint, a disease - whether common or rare -...
Avalyn Pharma Outlines IPO Fund Allocation, IVVD, REPL Updates
13April: How does Avalyn Pharma plan to spend the proceeds of the IPO for which it has filed paperwork? Read what's been made public about the company's planned initial public offering, plus updates on $IVVD and $REPL in my latest...
Daraxonrasib Halves Pancreatic Cancer Mortality, Doubles Survival
Finally, best news of the morning (and something you didn't expect so soon)... Revolution Medicines $RVMD daraxonrasib Ph3 results in second-line pancreatic cancer. Median overall survival in ITT patients (KRAS mutants + wild type combined) Dara 13.2 months vs chemo 6.7...
Allogeneic CAR‑T Achieves 42% MRD Boost, Safe Profile
Allogene $ALLO cema-cel interim ALPHA3 results just reported: B-cell lymphoma MRD negativity: cema-cel 58% vs observation 16% A 42% absolute difference in MRD clearance is better than expected. Clean safety profile, too. Allogeneic CAR-T may have found its role. Nice...
NVS Sells Darovasertib for $6M in Cash, Stock
Let's remember again that $NVS dumped off darovasertib for $2.5m in cash + $3.5m in $IDYA series B preferred stock.
Spyre's SPY001 Achieves 40% Remission in UC Trial
Spyre $SYRE just reported SPY001 (long-acting alpha4beta7 antibody) ulcerative colitis induction data. Here's the efficacy chart, notable for a 40% clinical remission rate at week 12, albeit with small number of patients. https://t.co/aEoLWPRjEL
LUT014 Shows Promise for RASi‑Induced Skin Rash
*Disclaimer : the company developing LUT014 is a Pontifax portfolio company.* Mechanistically LUT014 should be effective in RASi induced-rash as it was designed to activate RAS signaling in the skin so using it topically could de-couple RAS inhibition in the tumor...
High‑dose GLP‑1s Raise Optic Nerve Risk; Titrate Carefully
Patients are not asking if GLP-1s are right for them. They are asking how much you charge for tirzepatide. Shiv K. Goel breaks down what physicians need to know about oral Wegovy. Pharmacovigilance data: Wegovy carries nearly five times higher...
ALLO's Alpha-3 DLBCL Data Set to Spark Pre‑Market Move
Key $ALLO catalyst coming pre market today, with first data from cema-cel's Alpha-3 study in DLBCL consolidation. What to look for: https://t.co/a19BVEppqP
Darovasertib Shows Promise in Optimum-02 Uveal Melanoma Trial
$IDYA darovasertib data from registrational Optimum-02 trial in uveal melanoma are out. What to look for: https://t.co/1LQa0X6xJa
AI Powers Cancer Cures While Robots Learn Chores
AI is designing molecules that boost chemotherapy effectiveness by 70%, and humanoid robots are learning tasks by watching gig workers record themselves doing chores... we're literally teaching machines to cure cancer AND do our laundry.
Targeted mRNA Nanoparticles Halt Lung Tumors and Cachexia
Follistatin mRNA delivered via targeted lipid nanoparticles enables a dual therapeutic effect by simultaneously suppressing lung tumor growth and preventing cancer-associated muscle wasting (cachexia). https://t.co/56fCFZU0vk
IPSC Therapies Succeed; In‑vivo Reprogramming Remains Hype
your regular reminder that Yamanaka factor-driven production of iPSCs is already producing real medicine (eg dopaminergic neural progenitor for Parkinson's, cardiomyocyte sheets for heart failure & more) iPSC tech is not done in vivo... ppl isolate the well behaved cells away...
Daily Evoked Gamma Therapy Shows Safety and Cognitive Benefit
Safety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer’s disease 👉 “Our results demonstrate that 1-h daily treatment with [CogTx-001] was safe and well-tolerated and demonstrated potential clinical benefits in mild to moderate AD.” 🔘 Participants underwent...
24/7 Green Lab Services Available for $49‑$150
Great list of services from @americanwetware to ultimately have available 24/7. We have most of the green ones already in place w/ protocols in Ginkgo Cloud Lab for $49-$150, still need to add solubility measurement but can do that...
AbbVie’s Mirvetuximab Shows
AbbVie combo mirvetuximab posts 62.7% ORR; median DOR 11.2m. Efficacy boosts pipeline vs rich valuation and R&D hit. Trading insight: buy on pullback ahead of catalysts. 📈 — Viktor Kopylov, PhD, CFA More insights: t.me/si14Kopylov
Drugs May Slow, but Not Fully Reverse Aging
Just like we can't turn a human into a naked mole rat with drugs (requires too many specific molecular changes), I don't think we will fully reverse ageing pharmacologically. We may be able to slow human ageing with drugs, but reversing...
A Decade of DNA Innovation Powers AI‑Biology Convergence
Ten years ago, Emily Leproust had an idea to rewrite how DNA gets made. Most people thought it wouldn't work. Today, Twist Bioscience is the infrastructure layer for biotech and pharma worldwide. At SynBioBeta 2026, she's on the main stage with John...
Rare Diseases Need Molecular Surgery, Not Drug Barriers
The turning point for rare diseases, which affect >300 million people around the world. A call to get rid of its many structural obstacles, to consider it as molecular surgery unlike drug treatments gift link: https://t.co/DQ0OZ9tXXc https://t.co/RELCwTr88i
